964 - Real-world dalbavancin use for serious gram-positive bacterial infections: comparing outcomes between people who use and do not use drugs

Presenting Author(s)

• 

  Sarah Zambrano, MD (she/her/hers)

  Resident
  Brigham and Women's Hospital
  Jamaica Plain, MA, United States

  Slides

Co-Author(s)

• 

  Molly L. Paras, MD (she/her/hers)

  Fellowship Program Director, Assistant Professor
  Massachusetts General Hospital, Harvard Medical School
  Boston, MA, United States
• JS

  Joji Suzuki, MD

  Director, Division of Addiction Psychiatry
  Brigham and Women's Hospital / Harvard Medical School
  Boston, MA, United States
• 

  Jeffrey C. Pearson, PharmD

  Clinical Pharmacy Specialist, Infectious Diseases
  Brigham and Women's Hospital
  Boston, Massachusetts, United States
• HS

  Harry Schrager, MD

  Assistant professor of medicine
  Tufts Medical School/Newton Wellesley Hospital
  Newton, Massachusetts, United States
• JM

  Jason Mallada, PharmD, BCPS, BCIDP

  Clinical Pharmacist, Antimicrobial Stewardship, Infectious Diseases
  Newton-Wellesley Hospital
  Newton, Massachusetts, United States
• BD

  Brandon Dionne, PharmD, BCPS-AQ ID, AAHIVP

  Clinical Pharmacist
  Brigham and Women's Hospital
  Boston, MA, United States
• KF

  Katie Fairbank-Haynes, Masters

  Clinical Research Coodrinator
  Newton Wellsley Hospital
  Newton, Massachusetts, United States
• MK

  Marlene Kalter, MA

  Clinical Research Project Manager
  Newton-Wellesley Hospital
  Newton, Massachusetts, United States
• VS

  Veronica Szpak, MSc

  Research Assistant
  Brigham and Women's Hospital
  Boston, Massachusetts, United States
• SP

  Sara Prostko, BA/BM

  Clinical Research Coordinator
  Brigham and Women's Hospital
  Boston, Massachusetts, United States
• 

  Daniel A. Solomon, MD

  Assistant Professor of Medicine
  Brigham and Women's Hospital / Harvard Medical School
  Boston, MA, United States